• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫组化标志物CK5、CD117和EGFR在乳腺癌分子亚型中的表达与预后相关。

Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis.

作者信息

Schulmeyer Carla E, Fasching Peter A, Häberle Lothar, Meyer Julia, Schneider Michael, Wachter David, Ruebner Matthias, Pöschke Patrik, Beckmann Matthias W, Hartmann Arndt, Erber Ramona, Gass Paul

机构信息

Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany.

Würzburg University Hospital, Institut für Pathologie, Julius-Maximilians-Universität Würzburg, 97070 Würzburg, Germany.

出版信息

Diagnostics (Basel). 2023 Jan 19;13(3):372. doi: 10.3390/diagnostics13030372.

DOI:10.3390/diagnostics13030372
PMID:36766486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9914743/
Abstract

Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort-case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS ( = 0.04) and OS ( = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.

摘要

基于分子的乳腺癌亚分类对于确定乳腺癌的治疗方案和判断预后具有重要意义。本研究旨在使用包括细胞角蛋白5（CK5）、分化簇117（CD117）和表皮生长因子受体（EGFR）的生物标志物组合，评估三阴性乳腺癌（TNBC）和其他亚型患者的无病生存期（DFS）和总生存期（OS）相关的预后情况。这项队列病例研究将组织学确诊的乳腺癌作为队列组。在总共894例患者中，纳入了572例具有充分临床数据且保存有肿瘤组织的早期乳腺癌患者。使用免疫组化标志物CK5、CD117和EGFR，形成了两个亚组：一个是所有三种生物标志物均为阴性（TBN），另一个是三种生物标志物中至少有一种为阳性（非TBN）。在TNBC中，两个生物标志物亚组（TBN与非TBN）在DFS（P = 0.04）和OS（P = 0.02）方面存在显著差异，非TBN亚组的生存率（DFS和OS）更高。在本研究中，我们发现TNBC病变的非TBN亚组，即至少有一种CK5、CD117和/或EGFR生物标志物呈阳性，与更长的DFS和OS相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/93401b7e3080/diagnostics-13-00372-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/2e880051f71d/diagnostics-13-00372-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/86e4874cd56b/diagnostics-13-00372-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/51a9873bb586/diagnostics-13-00372-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/ca8399426dfa/diagnostics-13-00372-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/93401b7e3080/diagnostics-13-00372-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/2e880051f71d/diagnostics-13-00372-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/86e4874cd56b/diagnostics-13-00372-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/51a9873bb586/diagnostics-13-00372-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/ca8399426dfa/diagnostics-13-00372-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ae/9914743/93401b7e3080/diagnostics-13-00372-g005.jpg

相似文献

1
Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis.免疫组化标志物CK5、CD117和EGFR在乳腺癌分子亚型中的表达与预后相关。
Diagnostics (Basel). 2023 Jan 19;13(3):372. doi: 10.3390/diagnostics13030372.
2
Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.表皮生长因子受体（EGFR）和细胞角蛋白5/6免疫组化表达在三阴性乳腺癌中的预后影响
Ann Diagn Pathol. 2017 Jun;28:43-53. doi: 10.1016/j.anndiagpath.2017.01.009. Epub 2017 Feb 4.
3
Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.使用组合生物标志物对三阴性乳腺癌患者的预后进行分层
PLoS One. 2016 Mar 1;11(3):e0149661. doi: 10.1371/journal.pone.0149661. eCollection 2016.
4
Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.细胞角蛋白5/6、雄激素受体和p53的免疫组化共表达状态作为三阴性乳腺癌辅助化疗的预后因素
Med Mol Morphol. 2016 Mar;49(1):11-21. doi: 10.1007/s00795-015-0109-0. Epub 2015 May 26.
5
Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.基于免疫组织化学标志物的三阴性乳腺癌分子亚型的临床病理特征。
Histol Histopathol. 2012 Nov;27(11):1481-93. doi: 10.14670/HH-27.1481.
6
Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers.三阴性乳腺癌：与基底标志物免疫组化检测结果的相关性。
Am J Surg Pathol. 2010 Jul;34(7):956-64. doi: 10.1097/PAS.0b013e3181e02f45.
7
The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine.细胞角蛋白5/6和表皮生长因子受体在接受卡培他滨维持治疗的转移性三阴性乳腺癌中的预后及预测意义
Transl Cancer Res. 2021 Mar;10(3):1193-1203. doi: 10.21037/tcr-20-1760.
8
c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.基底样和非基底样三阴性乳腺癌中c-Met和ERβ的表达差异
Tumour Biol. 2016 Aug;37(8):11385-95. doi: 10.1007/s13277-016-5010-5. Epub 2016 Mar 11.
9
Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.三阴性乳腺癌与马来西亚女性的表皮生长因子受体（EGFR）、细胞角蛋白5/6（CK5/6）和原癌基因c-KIT表达有关。
BMC Clin Pathol. 2012 Sep 26;12:18. doi: 10.1186/1472-6890-12-18.
10
Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.三阴性乳腺癌（TNBC）患者中生存素和 EGFR 蛋白表达的预后价值。
Target Oncol. 2014 Dec;9(4):349-57. doi: 10.1007/s11523-013-0300-y.

引用本文的文献

1
Cytokeratin expression in breast cancer: from mechanisms, progression, diagnosis, and prognosis to therapeutic implications.细胞角蛋白在乳腺癌中的表达：从机制、进展、诊断、预后到治疗意义
Mol Cell Oncol. 2025 Jul 1;12(1):2526230. doi: 10.1080/23723556.2025.2526230. eCollection 2025.
2
Immunohistochemical Expression of IRE1 and PERK in Breast Cancer: Associations With Clinicopathological Characteristics and Survival Outcomes.IRE1和PERK在乳腺癌中的免疫组化表达：与临床病理特征及生存结果的关联
Cancer Diagn Progn. 2025 Jun 30;5(4):515-529. doi: 10.21873/cdp.10466. eCollection 2025 Jul-Aug.
3
Triple-Negative Papillary Carcinoma of the Breast: A Case Report.

本文引用的文献

1
An Epigenetic Role of Mitochondria in Cancer.线粒体在癌症中的表观遗传学作用。
Cells. 2022 Aug 13;11(16):2518. doi: 10.3390/cells11162518.
2
Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy.基于矢状位和轴位乳腺动态对比增强磁共振成像的深度学习模型预测新辅助化疗病理完全缓解的稳健性评估
J Pers Med. 2022 Jun 10;12(6):953. doi: 10.3390/jpm12060953.
3
Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes.双唾液酸神经节苷脂GD2在乳腺癌分子亚型中的表达差异
乳腺三阴性乳头状癌：一例报告
Cureus. 2024 Sep 9;16(9):e69020. doi: 10.7759/cureus.69020. eCollection 2024 Sep.
4
Additional prognostic value of polymorphisms within the 3'-untranslated region of programmed cell death pathway genes in early-stage breast cancer. 早期乳腺癌中细胞程序性死亡通路基因 3'非翻译区多态性的附加预后价值。
Front Immunol. 2024 Apr 16;15:1284579. doi: 10.3389/fimmu.2024.1284579. eCollection 2024.
5
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.新辅助化疗后残留三阴性乳腺癌的病理及免疫组化预后标志物
Front Oncol. 2024 Jan 10;13:1309890. doi: 10.3389/fonc.2023.1309890. eCollection 2023.
6
Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer.乳腺癌中 miR-221-3p 及其关键靶基因与上皮-间充质转化相关的临床意义及免疫特征分析。
Aging (Albany NY). 2024 Jan 6;16(1):322-347. doi: 10.18632/aging.205370.
Cancers (Basel). 2021 Nov 8;13(21):5577. doi: 10.3390/cancers13215577.
4
Mammographic density and prognosis in primary breast cancer patients.乳腺 X 线摄影密度与原发性乳腺癌患者预后的关系。
Breast. 2021 Oct;59:51-57. doi: 10.1016/j.breast.2021.06.004. Epub 2021 Jun 17.
5
Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers.线粒体突变与线粒体表观遗传学：聚焦于调控乳腺癌中氧化应激诱导反应。
Semin Cancer Biol. 2022 Aug;83:556-569. doi: 10.1016/j.semcancer.2020.09.012. Epub 2020 Oct 6.
6
PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer.PIWI样蛋白1和PIWI样蛋白2在乳腺癌中的表达
Cancers (Basel). 2020 Sep 24;12(10):2742. doi: 10.3390/cancers12102742.
7
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis.三阴性乳腺癌病理完全缓解与长期生存结局的相关性：一项荟萃分析。
Cancer Res. 2020 Dec 15;80(24):5427-5434. doi: 10.1158/0008-5472.CAN-20-1792. Epub 2020 Sep 14.
8
Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.成纤维细胞生长因子受体1（FGFR1）扩增对乳腺癌患者预后的影响。
Breast Cancer Res Treat. 2020 Nov;184(2):311-324. doi: 10.1007/s10549-020-05865-2. Epub 2020 Aug 27.
9
Breast MRI texture analysis for prediction of BRCA-associated genetic risk.用于预测 BRCA 相关遗传风险的乳腺 MRI 纹理分析。
BMC Med Imaging. 2020 Jul 29;20(1):86. doi: 10.1186/s12880-020-00483-2.
10
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.新辅助化疗后病理完全缓解对乳腺癌复发和生存的影响：一项综合荟萃分析。
Clin Cancer Res. 2020 Jun 15;26(12):2838-2848. doi: 10.1158/1078-0432.CCR-19-3492. Epub 2020 Feb 11.